We’re proud to announce the successful completion of the bioequivalence (BE) study for Enzalutamide 160 mg tablets, reducing the pill burden from 4 x 40 mg to just 1 tablet daily— without compromising efficacy.With 40% tablet size reduction for 40 mg and 80 mg, and 120 mg and 160 mg tablets engineered to match the reference 80 mg size, this innovation significantly improves swallowability and patient compliance.Importantly, it addresses recent USFDA & EMA label updates (2025) highlighting choking risks due to large tablet size, reinforcing our commitment to patient-centric design.Dossier readiness for US & EU markets is targeted by Q2 2026, with global expansion to follow.Kudos to our R&D team for this meaningful advancement in oncology care!
Globallux respects global intellectual property laws. Products under active patent protection or Supplementary Protection Certificates (SPCs) are not developed, manufactured, marketed, or supplied in any country or region where such rights are in force.” Additionally, we can put an additional slides for Business model and team introduction.